欧洲与美国DCD心脏移植的多中心回顾性比较研究
该多中心回顾性研究比较了欧洲与美国DCD心脏移植中心的供受体特征、术中参数及结局。欧洲供者年龄显著更高(37岁 vs 28岁;p < 0.001),受体1年生存率较低(86.6% vs 91.8%;p = 0.043),但1个月和3年生存率相似。在直接获取与保存(DPP)队列中,美国组1年生存率显著更高(91.2% vs 82.6%;p = 0.02);在胸腹常温区域灌注(taNRP)队列中,两地1年生存率相似。欧洲受体移植后机械循环辅助使用率更高(17.9% vs 11%;p = 0.03)。
要点
- 欧洲DCD供者年龄显著高于美国(37岁 vs 28岁;p < 0.001)。
- 欧洲受体1年生存率低于美国(86.6% vs 91.8%;p = 0.043),但1个月和3年生存率相似。
- DPP队列美国1年生存率更高(91.2% vs 82.6%;p = 0.02),taNRP队列两地相似。
核心结论
- 研究进一步证实了DCD心脏移植在美国和欧洲各中心的安全性和有效性,尽管供受体人口学特征和临床结局存在重要差异。
- 持续收集国际数据可能有助于发现改善结局的机会。
研究设计与样本
- 多中心回顾性观察性研究,纳入比利时、西班牙、英国和美国的22个心脏移植中心。
- 纳入各中心DCD项目启动至2023年1月1日期间所有接受DCD心脏移植的患者,删失日期为2024年1月1日。
- 主要结局为1年生存率,次要结局包括严重原发性移植物功能障碍和急性细胞排斥反应发生率。
主要发现
- 分析欧洲223例和美国281例患者数据。
- 欧洲DCD供者年龄显著高于美国(37岁 vs 28岁;p < 0.001)。
- 欧洲受体1年生存率低于美国(86.6% vs 91.8%;p = 0.043),但1个月和3年生存率相似。
- DPP队列中美国组1年生存率显著更高(91.2% vs 82.6%;p = 0.02);taNRP队列中两地1年生存率相似。
- 欧洲受体移植后机械循环辅助使用率更高(17.9% vs 11%;p = 0.03)。
临床怎么用
- 临床可参考本研究结果,在DCD心脏移植中关注供者年龄和移植后机械循环辅助需求的地域差异。
- 对于采用DPP策略的中心,可借鉴美国经验以优化1年生存率;taNRP策略下两地结局相似。
局限性
- 回顾性观察性设计可能存在选择偏倚和混杂因素。
- 研究仅纳入参与Outcomes after DCD Cardiac Transplantation Database的中心,外推性有限。
- 原文未报告严重原发性移植物功能障碍和急性细胞排斥反应的具体比较数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Donation after the circulatory determination of death (DCD) heart transplantation (HT) is becoming more widely adopted across the United States (US) and Europe. OBJECTIVE: This study compared donor and recipient demographics, intraoperative parameters, and outcomes between DCD HT centers in Europe and the US that contributed to the Outcomes after DCD Cardiac Transplantation Database. METHODS: This was a retrospective observational study across 22 HT centers in Belgium, Spain, the United Kingdom (UK), and the US. All patients undergoing DCD HT at participating centers, from the start of each center's DCD program through 01/01/2023, were included with censor date 01/01/2024. The primary outcome was 1-year survival. Secondary outcomes included severe primary graft dysfunction and incidence of acute cellular rejection. RESULTS: Data from 223 patients in Europe and 281 in the US were analyzed. DCD donors in Europe were significantly older (37 years vs 28 years; p < 0.001). Recipients in Europe had inferior 1-year survival (86.6% vs 91.8%; p = 0.043), but 1-month and 3-years survival were similar. 1-year survival in the direct procurement and preservation (DPP) cohort was significantly higher in the US group (91.2% vs 82.6%; p = 0.02). In the thoraco-abdominal normothermic regional perfusion (taNRP) cohort 1-year survival was similar between Europe and the US. Recipients in Europe had higher use of mechanical circulatory assist post-transplant (17.9% vs 11%; p = 0.03). CONCLUSION: This study further confirms the safety and efficacy of DCD HT across centers in the US and Europe, despite important differences in donor and recipient demographics and clinical outcomes. Continued collection of international data may identify opportunities to improve outcomes.
引用
- Louca JO, Öchsner M, Shah A, et al. A comparison of DCD heart transplantation in Europe and the United States: A multi-center, retrospective study. J Heart Lung Transplant. 2026. PMID: 41999800. doi:10.1016/j.healun.2026.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。